185 related articles for article (PubMed ID: 36946611)
41. Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy.
Urakami K; Wada K; Arai H; Sasaki H; Kanai M; Shoji M; Ishizu H; Kashihara K; Yamamoto M; Tsuchiya-Ikemoto K; Morimatsu M; Takashima H; Nakagawa M; Kurokawa K; Maruyama H; Kaseda Y; Nakamura S; Hasegawa K; Oono H; Hikasa C; Ikeda K; Yamagata K; Wakutani Y; Takeshima T; Nakashima K
J Neurol Sci; 2001 Jan; 183(1):95-8. PubMed ID: 11166802
[TBL] [Abstract][Full Text] [Related]
42. Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients.
Liguori C; Olivola E; Pierantozzi M; Cerroni R; Galati S; Saviozzi V; Mercuri NB; Stefani A
CNS Neurol Disord Drug Targets; 2017; 16(3):339-345. PubMed ID: 27934563
[TBL] [Abstract][Full Text] [Related]
43. Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis.
Sako W; Murakami N; Izumi Y; Kaji R
J Neurol Sci; 2015 May; 352(1-2):84-7. PubMed ID: 25868897
[TBL] [Abstract][Full Text] [Related]
44. Pathological properties of the Parkinson's disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease.
Neumann M; Müller V; Görner K; Kretzschmar HA; Haass C; Kahle PJ
Acta Neuropathol; 2004 Jun; 107(6):489-96. PubMed ID: 14991385
[TBL] [Abstract][Full Text] [Related]
45. Tau protein quantification in skin biopsies differentiates tauopathies from alpha-synucleinopathies.
Vacchi E; Lazzarini E; Pinton S; Chiaro G; Disanto G; Marchi F; Robert T; Staedler C; Galati S; Gobbi C; Barile L; Kaelin-Lang A; Melli G
Brain; 2022 Aug; 145(8):2755-2768. PubMed ID: 35485527
[TBL] [Abstract][Full Text] [Related]
46. Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression.
Song YJ; Halliday GM; Holton JL; Lashley T; O'Sullivan SS; McCann H; Lees AJ; Ozawa T; Williams DR; Lockhart PJ; Revesz TR
J Neuropathol Exp Neurol; 2009 Oct; 68(10):1073-83. PubMed ID: 19918119
[TBL] [Abstract][Full Text] [Related]
47. Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies.
Barthélemy NR; Gabelle A; Hirtz C; Fenaille F; Sergeant N; Schraen-Maschke S; Vialaret J; Buée L; Junot C; Becher F; Lehmann S
J Alzheimers Dis; 2016; 51(4):1033-43. PubMed ID: 26923020
[TBL] [Abstract][Full Text] [Related]
48. Contribution of the astrocytic tau pathology to synapse loss in progressive supranuclear palsy and corticobasal degeneration.
Briel N; Pratsch K; Roeber S; Arzberger T; Herms J
Brain Pathol; 2021 Jul; 31(4):e12914. PubMed ID: 33089580
[TBL] [Abstract][Full Text] [Related]
49. The AD tau core spontaneously self-assembles and recruits full-length tau to filaments.
Carlomagno Y; Manne S; DeTure M; Prudencio M; Zhang YJ; Hanna Al-Shaikh R; Dunmore JA; Daughrity LM; Song Y; Castanedes-Casey M; Lewis-Tuffin LJ; Nicholson KA; Wszolek ZK; Dickson DW; Fitzpatrick AWP; Petrucelli L; Cook CN
Cell Rep; 2021 Mar; 34(11):108843. PubMed ID: 33730588
[TBL] [Abstract][Full Text] [Related]
50. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms.
Sergeant N; Wattez A; Delacourte A
J Neurochem; 1999 Mar; 72(3):1243-9. PubMed ID: 10037497
[TBL] [Abstract][Full Text] [Related]
51. Assessment of APOE in atypical parkinsonism syndromes.
Sabir MS; Blauwendraat C; Ahmed S; Serrano GE; Beach TG; Perkins M; Rice AC; Masliah E; Morris CM; Pihlstrom L; Pantelyat A; Resnick SM; Cookson MR; Hernandez DG; Albert M; Dawson TM; Rosenthal LS; Houlden H; Pletnikova O; Troncoso J; Scholz SW
Neurobiol Dis; 2019 Jul; 127():142-146. PubMed ID: 30798004
[TBL] [Abstract][Full Text] [Related]
52. [Corticobasal degeneration and progressive supranuclear palsy--biochemical marker].
Urakami K; Nakashima K
Rinsho Shinkeigaku; 2002 Nov; 42(11):1162-4. PubMed ID: 12784694
[TBL] [Abstract][Full Text] [Related]
53. Disease specificity and pathologic progression of tau pathology in brainstem nuclei of Alzheimer's disease and progressive supranuclear palsy.
Dugger BN; Tu M; Murray ME; Dickson DW
Neurosci Lett; 2011 Mar; 491(2):122-6. PubMed ID: 21236314
[TBL] [Abstract][Full Text] [Related]
54. Phosphorylated c-MYC expression in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Ferrer I; Blanco R; Carmona M; Puig B
Neuropathol Appl Neurobiol; 2001 Oct; 27(5):343-51. PubMed ID: 11679086
[TBL] [Abstract][Full Text] [Related]
55. Distinct phosphorylation profiles of tau in brains of patients with different tauopathies.
Samimi N; Sharma G; Kimura T; Matsubara T; Huo A; Chiba K; Saito Y; Murayama S; Akatsu H; Hashizume Y; Hasegawa M; Farjam M; Shahpasand K; Ando K; Hisanaga SI
Neurobiol Aging; 2021 Dec; 108():72-79. PubMed ID: 34536819
[TBL] [Abstract][Full Text] [Related]
56. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies.
Ferrer I; Blanco R; Carmona M; Puig B
J Neural Transm (Vienna); 2001; 108(12):1397-415. PubMed ID: 11810404
[TBL] [Abstract][Full Text] [Related]
57. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.
Craig-Schapiro R; Perrin RJ; Roe CM; Xiong C; Carter D; Cairns NJ; Mintun MA; Peskind ER; Li G; Galasko DR; Clark CM; Quinn JF; D'Angelo G; Malone JP; Townsend RR; Morris JC; Fagan AM; Holtzman DM
Biol Psychiatry; 2010 Nov; 68(10):903-12. PubMed ID: 21035623
[TBL] [Abstract][Full Text] [Related]
58. AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies.
Vingtdeux V; Davies P; Dickson DW; Marambaud P
Acta Neuropathol; 2011 Mar; 121(3):337-49. PubMed ID: 20957377
[TBL] [Abstract][Full Text] [Related]
59. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
Holmberg B; Rosengren L; Karlsson JE; Johnels B
Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
[TBL] [Abstract][Full Text] [Related]
60. Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies.
Gibbons GS; Banks RA; Kim B; Changolkar L; Riddle DM; Leight SN; Irwin DJ; Trojanowski JQ; Lee VMY
J Neuropathol Exp Neurol; 2018 Mar; 77(3):216-228. PubMed ID: 29415231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
